Search results
Anosognosia: Everything You Need to Know
Verywell Health via Yahoo News· 2 days agoIf the frontal lobe doesn't recognize the symptoms of an illness, the person is left with the pre-illness self-image and a lack of insight into their...
Schizoid vs. Schizotypal Personality Disorders
Verywell Mind via Yahoo News· 2 days agoPrevalence and Causes Both schizoid personality disorder and schizotypal personality disorder are relatively uncommon. ...
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its...
Morningstar· 4 days agoThe Company’s plan to conduct this trial using a 120 mcg dose is based on feedback received from the U.S. Food and Drug Administration (FDA) following the recent receipt...
Many mental-health conditions have bodily triggers
The Economist· 1 day agoTHE TICS started when Jessica Huitson was only 12 years old. In fact, Jessica had an autoimmune condition brought on by a bacterial infection with Streptococcus. Ms Huitson is not alone in having ...
Rewiring Reality: Stanford Unveils the Brain’s Fault Lines in Psychosis
SciTechDaily· 2 days agoWhen the brain has trouble filtering incoming information and predicting what’s likely to happen,...
What Causes High Triglycerides? Risk Factors, Complications
Healthline· 3 days agoA high level of triglycerides may lead to serious conditions like stroke or heart attack. Your body...
Ancient DNA Decoded: Tracing Neurodegenerative Diseases to Prehistoric Herders
SciTechDaily· 16 hours agoA significant study reveals that genes associated with multiple sclerosis were introduced to...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 22 hours agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC Wainwright
ETF DAILY NEWS· 4 days agoReviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on ...
